Llwytho...
The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis
The glycoprotein sclerostin inhibits activation of the canonical Wnt pathway and thereby suppresses bone formation by inhibiting the osteoblasts. Additionally, sclerostin increases bone resorption by stimulating the production of receptor activator of nuclear factor kappa-β-ligand (RANKL). Romosozum...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Ther Adv Musculoskelet Dis |
|---|---|
| Prif Awduron: | , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
SAGE Publications
2018
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6009094/ https://ncbi.nlm.nih.gov/pubmed/29942362 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1759720X18775936 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|